AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Mar 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-03-19

Reporting Person: Foster-Cheek Kaye I (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-19	Common stock	M	6800	$47.33	Acquired	9000	Direct
2018-03-19	Common stock	S	6800	$81.97	Disposed	2200	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-19	Stock option (right to buy)	$47.33	M	6800	Disposed	2026-06-20	Common stock (6800)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.52. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017.